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The effect of 1-,-D-arabinofuranosyl-E-5-(2-broniovinyl)uracil (BV-araU), a new antiviral drug, on Epstein-
Barr virus (EBV) was studied and compared with those of E-5-(2-bromovinyl)-2'-deoxyuridine (BVdU) and
acyclovir (ACV). BV-araU effectively inhibited EBV replication both in superinfected Raji cells and in virus
producer P3HR-1(LS) cells,,as determined by density gradient centrifugation, in situ cytohybridization with an
EBV DNA probe, and cRNA-DNA hybridization. The 50% effective doses for viral DNA replication were 0.26,
0.06, and 0.3 ,M for BV-araU, BVdU, and ACV, respectively. The relative efficacy on the basis of the in vitro
therapeutic index was BVdU (6,500) > BV-araU (1,500) > ACV (850). Synthesis of EBV-induced polypeptides
with molecular weights of 145,000 and 140,000 was inhibited by these drugs. Kinetic analysis of reversibility
of inhibition of EBV DNA replication after removal of the drugs indicated that BV-araU, like BVdU, has a
more prolonged inhibitory effect than ACV. These results indicate that the 2' OH group in the arabinosyl
configuration of BV-araU results in marked reduction in anti-EBV activity while slightly diminishing
cytotoxicity.
i-3-D-Arabinofuranosyl-E-5(2-bromovinyl)uracil (BV-
araU), a congener of E-5-(2-bromovinyl)-2'-deoxyuridine
(BVdiJ) (2), has been shown to inhibit herpes simplex virus
type 1 and varicella-zoster virus (17-19). The only difference
between BV-araU and BVdU, is that BV-araU has a 2' OH
group in the arabinosyl configuration (Fig. 1). Although all
herpesviruses encode functional viral DNA polymerases,
the responses of the different herpesviruses to various nu-
cleoside analQgs are unpredictable. As part of our attempts
to evaluate structure-activity relations (1, 6), we decided to
test and compare the relative efficacies of BV-araU and
BVdU in parallel with acyclovir (ACV). The results clearly
indicate that BV-araU, although less active against Epstein-
Barr virus (EBV) than BVdU, is as potent as ACV and has
a comparable in vitro therapeutic index and a more pro-
longed inhibitory effect than ACV.
MATERIALS AND METHODS
Cell cultures. A highly productive virus-producer cell line,
P3HR-1(LS), derived by low-serum cloning (7) and nonpro-
ducer (Raji) cells were propagated in RPMI 1640 medium as
described previously (10). Cells were maintained in expo-
nential growth (13) by seeding at a density of 4 x 105 to 6 x
105 cells per ml.
Treatment of cells with drugs. Exponentially growing cells
were spun down and suspended for 14 days in fresh medium
containing different concentrations of drugs (15). At the end
of drug treatment, cells were harvested and the number of
EBV genome copies per cell was determined. In some
experiments, the drug-treated cells were released into drug-
free medium and incubated in medium containing 12-0-
* Corresponding author.
tetradecanoylphorbol-13-acetate (TPA) for an appropriate
time, as indicated.
Determination of EBV genome copies per cell. EBV DNA
was purified from virus isolated from the supematant fluids
of TPA-induced P3HR-1(LS) cells (10). In vitro synthlesis of
cRNA and cRNA-DNA hybridization on nitrocellulose fil-
ters were carried out as described elsewhere (14).
Determination of ED50 for virus replication and ED5* for cell
growth. Cells were treated with various drug concentrations.
During drug treatment, cells were counted daily. The num-
ber of cells after 4 days of growth was plotted against drug
concentration, and the cell 50% inhibitory dose (ID50) was
determined from the plot (15). The number of EBV genome
copies per cell after 14 days of drug treatment was plotted
against drug concentration, and the virus 50% effective dose
(ED50) was determined as detailed previously (15).
Equilibrium density centrifugation. Both superinfected and
mock-infected Raji cells were pelleted, and DNA was iso-
lated and processed for analysis in cesium chloride density
gradients (13).
In situ cytohybridization with a recombinant EBV DNA
probe. Cloned BamHI fragrnent V DNA, which contains the
large internal repeated sequence (IR1) within the EBV
genome, was labeled with biotin (Enzo Biochem) by nick
translation, according to the protocol of the manufacturer
and as described elsewhere (5).
In situ cytohybridization was performed in cell smears on
slides as detailed previously (9).
Polyacrylamide gel electrophoresis of EBV-induced poly-
peptides. Superinfected Raji cells were labeled with
[35S]methionine in the presence and absence of drugs (15,
16), and the proteins were analyzed on 7.5% polyacrylamide
gels (4).
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TABLE 1. Inhibitory action of BV-araU, BVdU, ACV
Dru'aED50 ID50 Therapeutic index
Druga (>'M) (>M) (ID50/ED50)
BV-araU 0.26 390 1,500
BVdU 0.055 360 6,500
ACV 0.3 255 850
a The results obtained for BVdU and ACV were not significantly different
from those reported previously (15, 16).
Nucleoside X Y
BV-araU OH CH=CHBr
BVdU H CH = CHBr
BUdR H Br
FIG. 1. Structures of BV-araU, BVdU, and BUdR.
RESULTS
Dose-dependent inhibition. Figure 2 shows the dose-depen-
dent effects of BV-araU, BVdU, and ACV on viral genomes
in P3HR-1(LS) cells cultured for 14 days in the presence of
drugs. EBV genome copies per cell decreased with increas-
ing drug concentrations in all cases but at different rates.
Assuming that the residual genome level (30 copies per cell)
achieved by an effective drug concentration (100 ,uM) is zero
and that the viral genome level before drug treatment is 100,
from the plot we determined that the ED50s for viral inhibi-
tion were 0.26, 0.055, and 0.3 ,uM for BV-araU, BVdU, and
ACV, respectively. The same graphical method was used to
determine the ID50s for cell growth. On the basis of these
data, we calculated the therapeutic index (ID5JED50). The
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FIG. 2. Dose-dependent inhibition of EBV DNA replication.
Exponentially growing P3HR-1(LS) cells were seeded at a density of
106 per ml and incubated in various concentrations of drugs for 14
days. EBV genome copy numbers per cell determined at each drug
concentration were the average of two determinations.
results are shown in Table 1. The relative efficacy on the
basis of the therapeutic index was BVdU (6,500) > BV-araU
(1,500) > ACV (850).
Effects of BV-araU on superinfected Raji cells. To establish
that the inhibitory effect of BV-araU on EBV DNA replica-
tion is a general phenomenon, we tested the drug in an
infection system instead of the virus-producing cell line.
Superinfection of Raji cells with P3HR-1(LS) virus results in
the shutdown of host functions and stimulation of viral DNA
synthesis of both the exogenous virus and the endogenous
EBV genomes (11, 15). A large quantity of EBV DNA was
synthesized after superinfection of Raji cells (Fig. 3B) com-
pared with the control (Fig. 3A), as measured by the
radioactivity incorporated into DNA banding at 1.718 g/cm3,
the density of EBV DNA. In contrast, viral DNA replication
was greatly reduced in the presence of 90 ,uM BV-araU (Fig.
3C). As observed in other studies, cell DNA synthesis is
suppressed in superinfected Raji cells even in presence of an
antiviral drug (11, 15). This effect is attributed to superinfec-
tion, not to an effect of the drug on cell DNA synthesis (6).
Inhibition of EBV DNA replication detected by in situ
cytohybridization. Since there is residual viral DNA in the
presence of an effective concentration of BV-araU, we
performed viral DNA hybridization in situ in both cell
systems, i.e., superinfected Raji and P3HR-1(LS) cells.
Figure 4 clearly indicates that EBV DNA synthesis was
detected in approximately 40% of P3HR-1(LS) cells (Fig.
4A) and in 80% of superinfected Raji cells (Fig. 4D). The
sensitivity of hybridization was calibrated so that endoge-
nous EBV episomes in P3HR-1(LS) and Raji cells were
below the level of detection. However, viral DNA synthesis
was completely inhibited in both cell systems in the presence
of BV-araU (Fig. 4B and C), indicating that the residual viral
DNA (see Table 2) was not due to a few cells continuing to
synthesize new linear EBV DNA.
Persistent effect of BV-araU. We previously reported that
the inhibitory action exerted by ACV was completely re-
versed by 11 days after removal of the drug (15). The same
reversibility experiment was performed for BV-araU. Figure
5 indicates that 14 days of drug treatment were needed for
BV-araU to reduce the viral genome numbers to the residual
level (30 copies per cell). Upon removal of BV-araU, the
viral genome copies per cell remained at low levels (30% of
the control level) for about 13 days, becoming gradually
restored to control levels of untreated cells after 35 days.
To determine whether TPA can override the inhibitory
effect of the drug and speed up the reversibility of viral
replication after drug removal, we applied TPA to P3HR-
1(LS) cells after exposure for 14 days to BV-araU, BVdU, or
ACV. Table 2 shows that without antiviral drug treatment,
TPA produced a fivefold increase in EBV genome copies
(440 to 2,395). In ACV-treated cells, EBV genome numbers
increased to 98% of the control levels within 7 days, whereas
it took significantly longer to reach the control level in cells
treated with either BVdU or BV-araU. The most effective
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FIG. 3. Inhibition of EBV DNA synthesis by BV-araU in superinfected Raji cells. EBV DNA synthesis was determined by measuring the
incorporation of 32P into viral DNA and analyzing the DNA by cesium chloride density gradient centrifugation.
FIG. 4. Inhibition of EBV DNA synthesis detected by in situ cytohybridization. The probe used was cloned BamHI fragment V DNA,
which contains the large internal repeated (IR1) sequence. The probe was labeled with biotin by nick translation. The technique clearly
distinguishes those cells that are synthesizing viral DNA at levels above the endogenous episomal content. (A) P3HR-1(LS); (B) P3HR-1(LS)
in the presence of BV-araU (90 ,uM); (C) superinfected Raji cells in the presence of BV-araU (90 ,uM); (D) superinfected Raji cells.
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TABLE 2. Effect of TPA on the replication of residual EBV
genomes in P3HR-1(LS) cells after treatment
with BV-araU, BVdU, and ACV
No. of EBV genome copies/cell
Drug (concn)
b
% Control
Drug treatmenta TPA induction" (day)
ACV (90 ,uM) 30 1,452 (4) 60
2,347 (7) 98
BVdU (50 ,uM) 30 98 (4) 4
220 (7) 9
487 (10) 20
1,896 (14) 79
BV-araU (90 ,uM) 30 395 (4) 16
950 (7) 40
2,270 (10) 95
2,289 (14) 96
None 440 2,395 (4) 100
a A 10-fold ED90 was used for 14 days.
b After 14 days of drug treatment, cells were spun down, washed, resus-
pended in TPA medium, and incubated for various times as specified.
antiviral drug, BVdU, had the most prolonged inhibitory
effect even in the presence of TPA.
Inhibition of EBV-associated polypeptides. Figure 6 shows
the results of an electropherogram of 35S-labeled polypep-
tides synthesized in superinfected Raji cells in the presence
and absence of drugs. Superinfected Raji cells (lane S),
compared with mock-infected cells (lane M), resulted in the
synthesis of at least seven new polypeptides with molecular
weights of 145,000 (145K), 140K, 135K, 110K, 85K, 55K,
and 32K, detected 24 h postinfection in a continuous labeling
experiment. In the presence of 90 ,uM BV-araU (lane B),
synthesis of 145K, 140K, 110K, and 85K polypeptides was
significantly inhibited. For comparison, the effects of 50 ,uM
BVdU (lane C) and 90 ,uM ACV (lane A) on polypeptide
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FIG. 5. Kinetics of inhibition and reversibility of EBV DNA
replication in P3HR-1(LS) cells treated with BV-araU (90 ,uM).
synthesis are shown in the adjacent lanes. The 135K protein
also appears relatively reduced by BV-araU, as do the 145K
and 140K proteins with BVdU and ACV. The three drugs
had similar effects on EBV-induced polypeptide synthesis,
except that the 85K polypeptide was markedly reduced by
BV-araU.
DISCUSSION
The present results show that the anti-EBV activity of
BV-araU decreases approximately fivefold (in terms of
ED50s) upon substitution of 2' H with an OH group in the
arabinosyl configuration (Fig. 1).
It should be noted that the dose-response curve (see Fig.
2) near the ED50 is more linear than that near the 90%
effective dose. Thus, for comparison of the potencies of
different drugs, ED50s are more precise and useful than 90%
effective doses.
Despite the loss of activity, the data clearly indicate that
BV-araU is more potent than ACV in inhibition of EBV in
vitro, as evidenced by the lower ED50 and higher therapeutic
index. It should be noted that both 5-iodo-2'-deoxyuridine
(IUdR) and 5-bromo-2'-deoxyuridine (BUdR), which are
structurely related to BVdU and BV-araU (Fig. 1), are
FIG. 6. Differential effects of BV-araU, BVdU, and ACV on the
synthesis of EBV-associated polypeptides. Lanes: S, superinfected
Raji cells; M, mock-infected Raji cells; A, B, and C, superinfected
Raji cells in the presence of ACV, BV-araU, and BVdU, respec-
tively.
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potent inducers rather than inhibitors of EBV replication
(our unpublished data); treatment of D98/HR-1 cells with
IUdR stimulates EBV replication (8).
The anti-EBV activity of BV-araU appeared to be selec-
tive in that it inhibited virus replication at drug concentra-
tions which were not cytotoxic or cytostatic in vitro. The
effect of BV-araU on EBV-associated polypeptides is con-
sistent with its antiviral activity. As is the case for most
antiviral drugs, the effects of these compounds on viral
polypeptide synthesis, although a secondary effect of the
drugs, could play a role in the inhibition of virus replication
(15).
DNA polymerases induced by both types 1 and 2 of herpes
simplex virus have integrally associated exonuclease activity
(20). Although not yet confirmed by others, there is some
indication that EBV-induced DNA polymerase also has
exonuclease activity (la). Exonuclease may play a role in
affecting drug action through excision of the terminally
incorporated drug moieties, allowing at least temporary
recovery of primer-template capability. Under these circum-
stances, the antiviral activity of a nucleoside analog with a
potential of chain termination due to lack of the 3' OH group,
as in the case of ACV (3), would be expected to be more
reversible than an analog that incorporates (12) but does not
possess the capability of termination, such as BVdU and
BV-araU. In fact, we have observed that ACV inhibition
of EBV is readily reversible, whereas BVdU and BV-araU,
like 9- (1,3 - dihydroxy -2 -propoxy - methyl)guanine (DHPG)
and 1-(2-deoxy-2-fluoro-,B-D-arabinofuranosyl)-5-methylura-
cil (FMAU) (11), are not as reversible.
We have recently carried out studies of structure-activity
relations with acyclic pyrimidine nucleosides (1). We have
found that modifications in the base structure reduce antivi-
ral activity, whereas substitutions on or in the pyrimidine
ring exhibit selective activity against EBV (1). Furthermore,
in studies with acyclic adenosine analogs, substitutions of
the 2,3-dihydroxypropyl group in (S)-9-(2,3-dihydroxy-
propyl)adenine [(S)-DHPA] with 2-phosphonylmethyl deriv-
atives such as in 9-(2-phosphonylmethoxyethyl)adenine
(PMEA) and in (S)-9-(3-hydroxy- 2-phosphonylmethoxy-
propyl)adenine [(S)-HPMPA] greatly enhance antiviral ac-
tivity (6). Similar structure-activity relation studies on 5-
substituted deoxyuridines have been reported (21).
Conjugation of the C-C double bond of the olefinic 5-
substituent was suspected as a key molecular feature af-
fecting antiviral activity (21).
The biochemical basis for the differences in biological
activities of these compounds is poorly understood. There is
clearly a need for further studies to define fully the molecular
features that promote antiviral activity.
ACKNOWLEDGMENTS
We thank Joseph S. Pagano for critical review of the manuscript,
M. Carolyn Smith and Etsuyo I. Choi for excellent technical help,
and Teri L. Lanier for typing the manuscript.
This work was supported by Public Health Service grants 5-POI-
CA-19014 and AI-17205 from the National Cancer Institute and the
National Institute of Allergy and Infectious Diseases.
LITERATURE CITED
1. Beauchamp, L. M., B. L. Serling, J. E. Kelsey, K. K. Biron, P.
Collins, J. Selway, J. C. Lin, and H. J. Schaeffer. 1988. The
effect of pyrimidine acyclic nucleosides related to 9-[(1,3-
dihydroxy-2-propoxy)methyl]guanine on herpesvirus. J. Med.
Chem. 31:144-149.
la.Clough, W. 1979. Deoxyribonuclease activity found in the
Epstein-Barr virus producing lymphoblastoid cells. Biochemis-
try 18:4517-4521.
2. De Clercq, E., J. Descamps, P. De Somer, P. J. Barr, A. S. Jones,
and R. T. Walker. 1979. (E)-5-(2-bromovinyl)-2'-deoxyuridine:
a potent and selective anti-herpes agent. Proc. Natl. Acad. Sci.
USA 76:2947-2951.
3. Elion, G. B. 1983. The biochemistry and mechanism of action of
acyclovir. J. Antimicrob. Chemother. 12(Suppl. B):9-17.
4. Laemmli, U. K. 1970. Cleavage of structural proteins during the
assembly of the head of bacteriophage T4. Nature (London)
227:680-685.
5. Langer, P. R., A. A. Waldrop, and D. C. Ward. 1981. Enzymatic
synthesis of biotin-labeled polynucleotide: novel nucleic acid
affinity probes. Proc. Natl. Acad. Sci. USA 78:6633-6637.
6. Lin, J.-C., E. DeClercq, and J. S. Pagano. 1987. Novel acyclic
adenine analogs inhibit Epstein-Barr virus replication. Antimi-
crob. Agents Chemother. 31:1431-1433.
7. Lin, J.-C., D. J. Nelson, C. U. Lambe, and E. I. Choi. 1986.
Metabolic activation of 9([2-hydroxy-1-(hydroxymethyl)ethoxy]
methyl)guanine in human lymphoblastoid cell lines infected with
Epstein-Barr virus. J. Virol. 60:569-573.
8. Lin, J.-C., and J. S. Pagano. 1980. Synthesis of chromosomal
proteins and Epstein-Barr virus DNA in activated Burkitt
somatic cell hybrids. Virology 106:50-58.
9. Lin, J.-C., and N. Raab-Traub. 1987. Two strains of Epstein-
Barr virus (B95-8 and a P3HR-1 subclone) that lack defective
genomes induce early antigen and cause abortive infection of
Raji cells. J. Virol. 61:1985-1991.
10. Lin, J.-C., J. E. Shaw, M. C. Smith, and J. S. Pagano. 1979.
Effect of 12-O-tetradecanoyl-phorbol-13-acetate on the replica-
tion of Epstein-Barr virus. I. Characterization of viral DNA.
Virology 99:183-187.
11. Lin, J.-C., M. C. Smith, Y. C. Cheng, and J. S. Pagano. 1983.
Epstein-Barr virus: inhibition of replication by three new drugs.
Science 221:578-579.
12. Lin, J.-C., M. C. Smith, E. I. Choi, E. DeClercq, A. Verbruggen,
and J. S. Pagano. 1985. Effect of (E)-5-(2-bromovinyl)-2'-
deoxyuridine on replication of Epstein-Barr virus in human
lymphoblastoid cell lines. Antiviral Res. l(Suppl. I):121-126.
13. Lin, J. C., M. C. Smith, and J. S. Pagano. 1982. Effect of
12-O-tetradecanoyl-phorbol-13-acetate on cell proliferation and
Epstein-Barr virus DNA replication. Virology 117:186-194.
14. Lin, J.-C., M. C. Smith, and J. S. Pagano. 1983. Activation of
latent Epstein-Barr virus genomes: selective stimulation of
synthesis of chromosomal proteins by a tumor promoter. J.
Virol. 45:985-991.
15. Lin, J.-C., M. C. Smith, and J. S. Pagano. 1984. Prolonged
inhibitory effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine
against replication of Epstein-Barr virus. J. Virol. 50:50-55.
16. Lin, J.-C., M. C. Smith, and J. S. Pagano. 1985. Comparative
efficacy and selectivity of some nucleoside analogs against
Epstein-Barr virus. Antimicrob. Agents Chemother. 27:971-
973.
17. Machida, H. 1986. Comparison of susceptibilities of varicella-
zoster virus and herpes simplex viruses to nucleoside analogs.
Antimicrob. Agents Chemother. 29:524-526.
18. Machida, H., A. Kuninaka, and H. Yoshino. 1982. Inhibitory
effects of antiherpesviral thymidine analogs against varicella-
zoster virus. Antimicrob. Agents Chemother. 21:358-361.
19. Machida, H., S. Sakata, A. Kuninaka, and H. Yoshino. 1981.
Antiherpesviral and anticellular effects of 1-p-D-arabinofura-
nosyl-E-5-(2-halogenovinyl)uracils. Antimicrob. Agents Che-
mother. 20:47-52.
20. Ostrander, M., and Y. C. Cheng. 1980. Properties of herpes
simplex virus type 1 and type 2 DNA polymerase. Biochim.
Biophys. Acta 609:232-245.
21. Sim, I. S., J. Goodchild, D. M. Meredith, R. A. Porter, R. H.
Raper, J. Viney, and H. J. Wadsworth. 1983. Possible molecular
basis for antiviral activity of certain 5-substituted deoxyuri-
dines. Antimicrob. Agents Chemother. 23:416-421.
1072 LIN AND MACHIDA
 on July 14, 2020 by guest
http://aac.asm
.org/
D
ow
nloaded from
 
